Payment overview · 2025
General Payments
$47,782.39
395 reported records · 38 companies
Healthcare provider profile · identity verified
Scott H Goodman, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · OMAHA, NE · NPI 1265434443
Verified facts
What the public records show
CMS Open Payments records show Scott H Goodman, M.D. received $47,782.39 in general payments during 2025 across 395 reported records.
Axsome Therapeutics, Inc. accounted for 73.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 49 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Inbrija, Nuplazid, Nurtec Odt, Qulipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Ubrelvy by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Nuplazid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REYVOW as an associated drug or biological on 378 records involving 290 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Reyvow by this doctor in 2024.
Merz Pharmaceuticals, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INBRIJA as an associated drug or biological on 4307 records involving 2211 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Inbrija by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $35,291.74 | 73.9% | 48 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $8,358.82 | 17.5% | 57 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $348.44 | 0.7% | 24 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $338.94 | 0.7% | 22 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $322.70 | 0.7% | 22 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $303.82 | 0.6% | 25 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $240.50 | 0.5% | 22 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $206.65 | 0.4% | 23 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $204.67 | 0.4% | 27 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $198.10 | 0.4% | 27 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $195.62 | 0.4% | 17 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $161.17 | 0.3% | 11 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $153.03 | 0.3% | 5 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $151.59 | 0.3% | 8 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $134.80 | 0.3% | 4 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $83.61 | 0.2% | 3 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $82.74 | 0.2% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $76.79 | 0.2% | 4 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $73.25 | 0.1% | 3 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$70.12 | 0.1% | 3 | 2025 |
| HOSPIRA, INC. | Unresolved — no canonical attribution shown | $69.24 | 0.1% | 4 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $68.19 | 0.1% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $67.13 | 0.1% | 3 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$65.72 | 0.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $59.91 | 0.1% | 3 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $56.26 | 0.1% | 3 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $48.50 | 0.1% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.47 | 0.1% | 2 | 2025 |
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $45.19 | 0.1% | 2 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $44.70 | 0.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $40.99 | 0.1% | 2 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $38.54 | 0.1% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $25.58 | 0.1% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $24.00 | 0.1% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $23.56 | 0.1% | 1 | 2025 |
| Impel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $21.55 | 0.1% | 1 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $19.75 | 0.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.01 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Honoraria | $30,937.50 | 9 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,956.25 | 2 |
| Food and Beverage | $5,606.31 | 367 |
| Travel and Lodging | $4,258.91 | 15 |
| Education | $23.42 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $35,265.07 | 46 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $8,072.68 | 26 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $338.94 | 22 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $322.70 | 22 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $303.82 | 25 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | HOSPIRA, INC., PFIZER INC. | $269.05 | 12 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $228.41 | 24 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $206.65 | 23 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $195.62 | 17 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $182.50 | 25 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $168.34 | 25 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $161.17 | 11 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $148.63 | 16 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $148.63 | 16 | 2025 |
Source payment records
|
|||||
| Mavenclad Normalized: mavenclad |
Drug | EMD Serono, Inc. | $121.60 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Biological, Drug | HOSPIRA, INC., Octapharma USA, Inc., PFIZER INC. | $105.47 | 5 | 2025 |
Source payment records
|
|||||
| Dysport Normalized: dysport |
Drug | Ipsen Biopharmaceuticals, Inc | $83.61 | 3 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $82.74 | 4 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $80.15 | 15 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $76.79 | 4 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $73.25 | 3 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $68.19 | 3 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $67.13 | 3 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $65.72 | 3 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $56.98 | 4 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $48.50 | 2 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $47.47 | 2 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $44.70 | 2 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $42.09 | 2 | 2025 |
Source payment records
|
|||||
| EMGALITY Normalized: emgality |
Drug | Lilly USA, LLC | $41.61 | 2 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $40.99 | 2 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $38.54 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $34.41 | 2 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $34.14 | 2 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $33.95 | 4 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SENTIVA MODEL 1000 GENERATOR Normalized: vns therapy sentiva model 1000 generator |
Device | LivaNova USA, Inc. | $31.15 | 1 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $30.02 | 4 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $27.02 | 4 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $26.67 | 2 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $25.58 | 1 | 2025 |
Source payment records
|
|||||
| ZEMBRACE SYMTOUCH Normalized: zembrace symtouch |
Drug | Tonix Medicines, Inc. | $24.00 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $23.56 | 1 | 2025 |
Source payment records
|
|||||
| TRUDHESA Normalized: trudhesa |
Drug | Impel Pharmaceuticals LLC | $21.55 | 1 | 2025 |
Source payment records
|
|||||
| QALSODY Normalized: qalsody |
Drug | Biogen, Inc. | $20.68 | 1 | 2025 |
Source payment records
|
|||||
| SPINRAZA Normalized: spinraza |
Biological | Biogen, Inc. | $20.68 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $19.01 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| VNS Therapy Normalized: vns therapy |
Device | LivaNova USA, Inc. | $14.04 | 1 | 2025 |
Source payment records
|
|||||
| CUTAQUIG Normalized: cutaquig |
Biological | PFIZER INC. | $7.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| INBRIJA inbrija |
2025 | Inbrija | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 43 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
43 | 12 |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | REYVOW open payments reported associated product |
CMS Open Payments — General Payments 378 supporting records · 290 recipient NPIs · example record 1186470979 |
Reyvow · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Merz Pharmaceuticals, LLC Exact reporting entity; no affiliate inference |
2025 | INBRIJA open payments reported associated product |
CMS Open Payments — General Payments 4307 supporting records · 2211 recipient NPIs · example record 1232555387 |
Inbrija · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Topiramate | Topiramate | 251 | 45 |
| Gabapentin | Gabapentin | 198 | 48 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 190 | 47 |
| Emgality Pen | Galcanezumab-Gnlm | 155 | 24 |
| Primidone | Primidone | 135 | 18 |
| Levetiracetam | Levetiracetam | 116 | 26 |
| Divalproex Sodium Er | Divalproex Sodium | 93 | 18 |
| Sumatriptan Succinate | Sumatriptan Succinate | 87 | 12 |
| Pregabalin | Pregabalin | 76 | 13 |
| Lamotrigine | Lamotrigine | 69 | 23 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 68 | 13 |
| Aimovig Autoinjector | Erenumab-Aooe | 62 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 61 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 56 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 55 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 50 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 49 | 15 |
| Baclofen | Baclofen | 48 | 14 |
| Propranolol Hcl Er | Propranolol Hcl | 45 | suppressed |
| Verapamil Er | Verapamil Hcl | 45 | suppressed |
| Ubrelvy | Ubrogepant | 43 | 12 |
| Nortriptyline Hcl | Nortriptyline Hcl | 41 | suppressed |
| Carbamazepine Er | Carbamazepine | 29 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 29 | suppressed |
| Clonazepam | Clonazepam | 28 | suppressed |
| Qulipta | Atogepant | 28 | suppressed |
| Reyvow | Lasmiditan Succinate | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 24 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 24 | suppressed |
| Zonisamide | Zonisamide | 24 | suppressed |
| Kesimpta Pen | Ofatumumab | 23 | suppressed |
| Zolmitriptan | Zolmitriptan | 23 | suppressed |
| Acetazolamide | Acetazolamide | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 16 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 13 |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Nadolol | Nadolol | 15 | suppressed |
| Phenobarbital | Phenobarbital | 15 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | suppressed |
| Rivastigmine | Rivastigmine | 14 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 13 | suppressed |
| Dalfampridine Er | Dalfampridine | 13 | suppressed |
| Pramipexole Er | Pramipexole Di-Hcl | 13 | suppressed |
| Trokendi Xr | Topiramate | 13 | suppressed |
| Ajovy Syringe | Fremanezumab-Vfrm | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Cambia | Diclofenac Potassium | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 12 | suppressed |
| Tetrabenazine | Tetrabenazine | 12 | suppressed |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 11 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 11 | suppressed |
| Entacapone | Entacapone | 11 | suppressed |
| Inbrija | Levodopa | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $47,782.39 · 395 records | Axsome Therapeutics, Inc. | AUSTEDO XR, BOTOX, BRIUMVI, Briviact, CREXONT, CUTAQUIG, Dysport, EMGALITY, EPIDIOLEX, FYCOMPA, Fintepla, Gocovri, Hizentra, INBRIJA, INGREZZA, KESIMPTA, KISUNLA, Leqembi, Mavenclad, NUPLAZID, NURTEC ODT, Nayzilam, OCTAGAM IMMUNE GLOBULIN (HUMAN), Ocrevus Zunovo, PANZYGA, PONVORY, PURIFIED CORTROPHIN GEL, QALSODY, QULIPTA, REXULTI, Rystiggo, SPINRAZA, Sunosi, Symbravo, TRUDHESA, TYSABRI, UBRELVY, UPLIZNA, VALTOCO, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, VNS Therapy, VUMERITY, VYALEV, VYEPTI, WAINUA, Xeomin, ZAVZPRET, ZEMBRACE SYMTOUCH, ZEPOSIA | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Inbrija play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error